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A B S T R A C T
We present a case of donor-derived tuberculosis after 
liver transplantation, in which the donor origin of the 
Mycobacterium tuberculosis isolate was made most likely 
by DNA fingerprinting. Screening for latent tuberculosis 
of transplant donors originating from high endemic areas 
with an ex-vivo interferon-gamma release assay should be 
considered.
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I N T R O D U C T I O N
Donor-derived infections remain a challenge after solid 
organ transplantation because screening of post-mortal 
donors is not possible for all potential pathogens. Whereas 
transmission of pathogens such as cytomegalovirus and 
Epstein-Barr virus is a known and accepted risk, other 
infections may be transmitted unexpectedly. Although 
the incidence of donor-derived infections is low at 
approximately 0.2%, recipient mortality may be as high 
as 25%.1,2 We present a case of donor-derived tuberculosis 
after liver transplantation, in which the donor origin of the 
Mycobacterium tuberculosis isolate could be demonstrated 
by DNA fingerprinting.
C A S E  R E P O R T
A 70-year-old man, born in Suriname, was referred 
to our centre with rapidly progressive liver failure. 
His medical history consisted of recent cholecystitis, 
treated conservatively with amoxicillin-clavulanic acid. 
On admission, the Model for End-Stage Liver Disease 
(MELD) score was 23. Further workup excluded infectious, 
hereditary, vascular and autoimmune disorders. During 
pre-transplant screening, a tuberculin skin test and 
interferon gamma release assay (Quantiferon-TB Gold 
in-tube®) were both negative and chest radiography showed 
no abnormalities. 
Due to progressive liver failure, the patient underwent 
orthotopic liver transplantation in November 
2013. The donor was a 57-year-old woman from the 
Philippines who suffered from a lethal brain injury 
after a complicated resection of a pituitary adenoma. 
Histopathology of the recipient’s explanted liver showed 
nodular regenerative hyperplasia and bland cholestasis, 
suggesting drug-induced liver injury as the cause of liver 
failure. Maintenance immunosuppression consisted of 
prednisolone and tacrolimus.
Six months post-transplantation the patient developed fever 
without other symptoms. A CT scan showed a mass of 3.3 
× 3.7 cm in the liver hilum with portal vein thrombosis 
due to compression (figure 1). A diagnostic aspiration 
yielded pus. The Gram stain showed 5-20 leukocytes and 
0-5 Gram-positive rods per high power field. Additional 
Ziehl-Neelsen staining showed +4 acid fast bacilli and a 
PCR for M. tuberculosis (MTB) complex (in-house, IS6110 
target) was positive. Culture for common aerobic and 
anaerobic bacteria remained negative. 
Since 1993, in the Netherlands all MTB isolates are 
routinely fingerprinted for epidemiological purposes 
at the Tuberculosis Reference Laboratory. Based on 
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spoligotyping, the MTB isolate found in the present case 
was characteristic of the Manilla genotype family, which 
is commonly found in immigrants originating from the 
Philippines.3 Based on the genotype, characteristic of the 
donor’s origin, it was concluded that the infection was 
probably donor-derived. During pre-transplant screening 
of the donor, abdominal ultrasound and chest radiography 
showed no abnormalities. No tests for latent tuberculosis 
had been performed. The infection was reported to 
Eurotransplant. To date, the recipients of the kidneys 
and pancreas of the same donor have not developed 
tuberculosis.
Treatment consisted of isoniazid, ethambutol, 
pyrazinamide and levofloxacin and a portal stent was 
placed. Rifampicin was not used because of the interaction 
with tacrolimus. The isolate was later found to be fully 
susceptible. Pyrazinamide was discontinued after five 
weeks because of rising uric acid levels and levofloxacin 
was discontinued after seven weeks because the patient 
wanted to resume running. It was planned to treat him for 
18 months. However, after eight months of treatment the 
serum aminotransferases were elevated (SGOT 229 IU/l, 
SGPT 553 IU/l). The tuberculosis therapy was discontinued 
followed by normalisation of the liver enzymes. Because 
imaging showed complete resolution of the abscess, the 
treatment was not resumed and the patient remained well, 
the follow-up time being 29 months at the time of this 
writing.
D I S C U S S I O N
Infections are among the most frequent complications 
after solid organ transplantation. They can be categorised 
as a manifestation of pre-existing chronic infection in the 
recipient, a reactivation of latent infection in the recipient, 
a donor-derived infection or as exogenous de novo infection. 
The percentage of infections that are donor-derived varies 
in different reports.4,5 
The incidence of tuberculosis in solid organ transplant 
recipients is higher than in the general population.6,7 
The differentiation between endogenous reactivation and 
donor-derived infection can be difficult. A donor origin is 
very likely if infection is only localised in the transplanted 
organ or if multiple recipients from the same donor 
develop tuberculosis with an identical isolate.
Donor-derived tuberculosis from a liver transplant is rare, 
with only a few published cases.8-10 In contrast to the lack 
of proof in those reports, the donor origin of the infection 
in our patient was deducted from the MTB fingerprint in 
combination with the donor origin from the Philippines, 
where that specific MTB genotype was known to circulate. 
While post-transplant tuberculosis is notorious for poor 
graft and patient survival, the early diagnosis with only 
localised disease probably contributed to a favourable 
outcome.11 
Potential organ donors are thoroughly screened to reduce 
the risk of transmission of infections. Eurotransplant 
guidelines prescribe which information is required to 
minimalise this risk. Specific screening of living donors 
for latent tuberculosis is possible, although there is 
debate on the value of such screening and the need for 
treatment.12 In case of post-mortal donors, screening for 
tuberculosis with skin testing is generally not feasible and 
the donor origin, a history of past tuberculosis or exposure 
and chest radiography have a very limited sensitivity for 
latent tuberculosis. Screening with a tuberculosis-specific 
interferon gamma release assay, which only requires a 
fresh blood sample, could be useful.12 
The treatment of tuberculosis in transplant recipients can 
be challenging due to drug interactions and significant 
toxicity. According to current guidelines, treatment 
should be based on epidemiology and drug resistance.13 
Figure 1. CT scan of the abdomen (upper panel 
coronal view; lower panel transverse view), arrows 
indicate the abscess located at the liver hilum
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Treatment with a rifamycin is generally avoided because 
of interactions with calcineurin inhibitors and mTOR 
inhibitors. If a rifamycin is nevertheless used, the dose 
of immunosuppressive drugs has to be increased with 
close monitoring of drug levels. Significant hepatotoxicity 
can occur, especially when combining several hepatotoxic 
drugs including pyrazinamide, rifampicin and 
isoniazid.14,15 Consultation with a tuberculosis expert 
is always indicated in case of post-transplantation 
tuberculosis.
C O N C L U S I O N
This case with donor-derived tuberculosis after liver 
transplantation illustrates that donors originating from 
high tuberculosis endemic countries may transmit 
tuberculosis via a transplanted liver, although this is 
probably very rare. The early diagnosis probably 
contributed to the favourable outcome in our patient. 
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